Moderna halts development of birth defect vaccine after trial setback

Moderna said on Wednesday it would stop developing its experimental vaccine to prevent cytomegalovirus, a virus that can ...
Medscape

No Signal for Myocarditis in Updated Moderna mRNA COVID Vaccine

Small study looks only at a cardiac biomarker; findings are in line with reduced myocarditis risk in mRNA COVID vaccines ...
Fierce Biotech

Moderna scraps congenital virus program after vaccine shows little protective effect in phase 3

Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women ...
Fierce Biotech

ESMO: Moderna's oncology efforts 'make sense' while government skeptical of vaccines

Moderna’s oncology pipeline also includes a Merck-partnered personalized cancer vaccine called intismeran autogene or ...
BioPharma Dive

Moderna says CMV vaccine once seen as future blockbuster fails key study

A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, ...

Moderna Drops Vaccine for Birth Defects After Trial Failure

Moderna had hoped its shot would be at least 49% effective at preventing CMV infections, substantially reducing the risk of ...

Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint

(NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...
GlobalData on MSN

Moderna scraps mRNA vaccine in congenital CMV on Phase III failure

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

Moderna says key study of its CMV vaccine, expected to be its next big win, failed

It's a significant setback for the Cambridge company, which is already facing pressure from Wall Street and the federal ...

Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Prediction: Moderna Will Soar Over the Next 5 Years. Here's 1 Reason Why.

The biotech's innovative qualities will come in handy. Long gone are the days when Moderna ( MRNA 2.66%) would generate over ...

Moderna Named a Top Employer by Science for Eleventh Consecutive Year

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers ...